Multiple Sclerosis Resource Centre
  • Home
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • The Best Bet Diet Group
  • Advertising
  • MSRC Guest Book
  • E-Newsletter
  • Contact Us
  • Investor in People
    You are here : Home » Get Involved » MSRC Interactive » Tysabri® User Diaries

    Tysabri® User Diaries

    A A A
    [Print this page]

    Share |

    TysabriTo aid those who may have been prescribed Tysabri® or those thinking of asking their Neurologist to prescribe Tysabri®.

    We at the MSRC have enlisted the help of a number of people with MS who are now currently taking Tysabri® to provide some insight into how they went about getting given the drug and how the monthly infusions have changed, or not, their condition.

    If you are currently taking Tysabri®, and would like to join our panel of "Diarists" please contact the MSRC Webmaster at [email protected]

    Tysabri® Diarists

    Useful Tysabri® Information

    For more information on Tysabri please have a look at the "The Strength to Reach Your High HOPES" - Tysabri Information Booklet, UK patients please note this is a US publication, but contains much useful information.

    What is Tysabri®?

    TYSABRI® (Natalizumab) is a treatment approved for relapsing forms of Multiple Sclerosis in the United States and relapsing-remitting MS in the European Union.

    It is a recombinant humanised monoclonal antibody produced in murine myeloma cells. The specific mechanism(s) by which TYSABRI® exerts its effects in multiple sclerosis have not been fully defined. However, Pharmacodynamic data has shown that TYSABRI® administration increases the number of circulating leukocytes (including lymphocytes, monocytes, basophils, and eosinophils) due to inhibition of transmigration out of the vascular space. TYSABRI® does not affect the number of circulating neutrophils.

    According to data that have been published in the New England Journal of Medicine, after two years, Tysabri® treatment led to a 68% relative reduction (p<0.001) in the annualised relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001).

    In addition to the United States and European Union, Tysabri® is also approved for MS in Switzerland, Canada, Australia, New Zealand and Israel. Tysabri® was discovered by Elan and is co-developed with Biogen Idec.

    Source: Biogen Idec.

    © Multiple Sclerosis Resource Centre (MSRC)

    Related Items
    Ade's Tysabri Diary
    Amy Kristine's Tysabri Diary
    Cheryl's Tysabri Diary
    Christine B's Tysabri Diary
    Christine's Tysabri Diary
    David's Tysabri Diary
    Deborah Penny's Tysabri Diary
    Diane's Tysabri Diary
    Donna T's Tysabri Diary
    Eddie Clark's Tysabri Diary
    Emma's Tysabri Diary
    Ewizabeth's Tysabri Diary
    Georgina's Tysabri Diary
    Jan's Tysabri Diary
    Jill's Tysabri Diary
    John W's Tysabri Diary
    Karen's Tysabri Diary
    Kate's Tysabri Diary
    Lauren's Tysabri Diary
    Mandy's Tysabri Diary
    Martha Rogers' Tysabri Diary
    Melissa's Tysabri Diary
    Michelle's Tysabri Diary
    Nicky's Tysabri Diary
    Patti's Tysabri Diary
    Paula's Tysabri Diary
    Richard's Tysabri Diary
    Sarah P's Tysabri Diary
    Sarah's Tysabri Diary
    Shane's Tysabri Diary
    Stuart S's Tysabri Diary
    Sue Lawrence's Tysabri Diary
    Susan's Tysabri Diary
    Tariq's Tysabri Diary
    Tony's Tysabri Diary
    Have Your Say
    Help, Advice and Inspiration from people with MS

    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.